These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15585616)

  • 41. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
    Singh SK; Luisi DL; Pak RH
    Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody Drug Conjugates: Preclinical Considerations.
    Bornstein GG
    AAPS J; 2015 May; 17(3):525-34. PubMed ID: 25724883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimising the delivery of tubulin targeting agents through antibody conjugation.
    Stack GD; Walsh JJ
    Pharm Res; 2012 Nov; 29(11):2972-84. PubMed ID: 22777294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
    J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
    Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
    Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers.
    Smith LM; Nesterova A; Ryan MC; Duniho S; Jonas M; Anderson M; Zabinski RF; Sutherland MK; Gerber HP; Van Orden KL; Moore PA; Ruben SM; Carter PJ
    Br J Cancer; 2008 Jul; 99(1):100-9. PubMed ID: 18542072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
    Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Issues related to targeted delivery of proteins and peptides.
    Lu Y; Yang J; Sega E
    AAPS J; 2006 Jul; 8(3):E466-78. PubMed ID: 17025264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
    Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.